Blackhawk Growth Corp. is preparing to launch Talk to Doc RX — an on-line pharmacy delivery service directly interconnected to the company’s recently launched telemedicine platform. This feature will allow doctors utilizing the platform to send their patients prescriptions directly to participating pharmacies that will then be adding the additional service of delivering fulfilled prescriptions directly to their patient’s homes.

In addition, Blackhawk has been in discussions with a logistics delivery partner that has a pre-existing relationship with a notable national pharmacy chain to further expand on the direct-to-home prescription fulfillment. The launch of this feature is part of the Corporation’s ongoing efforts to expand the telemedicine platform and gain further investment exposure to the healthcare sector. Use of this feature in particular provinces or territories of Canada is dependent on licensing arrangements made by the participating pharmacy in that jurisdiction.

“Delivery of prescriptions amid the Covid-19 pandemic is not only an essential need and a prudent next step for Blackhawk’s telemedicine offerings but also a beneficial service to be utilized in a post Covid-19 world,” says Frederick Pels, chief executive officer of Blackhawk. “The launch of this direct to consumer delivery extension provides Blackhawk’s shareholders with added value for our investment in and further establishes our footprint in Canada’s growing telehealth infrastructure.”

This feature was an initiative built in tandem with Heally, Inc., a San Francisco based telemedicine company. Details of the partnership with Heally, Inc. are currently being contemplated between both companies and once an agreement has been reached the Corporation will provide further details.

“This was a natural next step for us”, adds Frederick Pels. “This extension is fully built and the team at Heally, Inc. is ready to launch once we have secured our delivery and pharmacy partners. The value-add here is significant for the future of Blackhawk and is another great step forward for us as we expand our interest in the smart healthcare space. The ability to work with the team at Heally has given us the required flexibility to make an impact so Canadians can stay safe and healthy in these uncertain times. We truly believe that seeing a doctor virtually is the way of the future and having a pharmacy deliver your medication to you without having to leave your home will set us apart from everyone else in the industry.”

Blackhawk is also excited to announce that its common shares have been listed on the Frankfurt Stock Exchange under the trading symbol 0JJ. The Corporation’s common shares continue to be listed on the Canadian Securities Exchange under the trading symbol BLR.

“Many of the investment opportunities presented to Blackhawk have an international reach,” says Frederick Pels, CEO of Blackhawk. “Listing on the Frankfurt Stock Exchange gives us the ability to expand our shareholder base throughout Europe. This is a major move towards furthering the objectives of improving our visibility within the investment community and increasing investor awareness globally. We look forward to exposing our story to new investors and keeping our shareholders abreast of our investment plans over the coming months.”

For further information please contact:

Frederick Pels, Chief Executive Officer

This email address is being protected from spambots. You need JavaScript enabled to view it.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the fulfillment of an order for the delivery of COVID-19 testing kits, and anticipated future orders. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.